PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 11, 2013, Pages 1917-1925

  Du, Qing Qing ^a   Wang, Zhi Jun ^b   He, Lin ^c   Jiang, Xue Hua ^a   Wang, Ling ^a  

^a SICHUAN UNIVERSITY   (China)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

CYP3A4; Drug interaction; Flucloxacillin; Pharmacogenetics; PXR; Repaglinide

Indexed keywords

CYTOCHROME P450 3A4; FLUCLOXACILLIN; PREGNANE X RECEPTOR; REPAGLINIDE;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG POTENTIATION; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PXR GENE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CARBAMATES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FLOXACILLIN; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID;

EID: 84886770537     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1552-2     Document Type: Article

References (26)

1. McGraw J, Waller D (2012) Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Met 8(3):371-382
2. Lin J (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23(6):1089-1116
3. Shargel L, Wu-Pong S, Yu ABC (2004) Applied biopharmaceutics & pharmacokinetics. McGraw-Hill Medical Publishing Division, New York
4. Mizutani T (2003) PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35(2-3):99-106
5. Pilgrim J, Gerostamoulos D, Drummer O (2011) Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Sci Med Pat 7(2):162-184
6. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuß C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29(11):1454-1459
7. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41-57
8. Hasegawa M, Tahara H, Inoue R, Kakuni M, Tateno C, Ushiki J (2012) Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver. Drug Metab Dispos 40(3):474-480
9. Rahmioglu N, Heaton J, Clement G, Gill R, Surdulescu G, Zlobecka K, Hodgkiss D, Ma Y, Hider RC, Smith NW, Ahmadi KR (2001) Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genom 21(10):642-651
10. Lim YP, Liu CH, Shyu LJ, Huang JD (2005) Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet Genom 15(5):337-341
11. Lim YP, Jd H (2007) Pregnane X receptor polymorphism affects CYP3A4 induction via a ligand-dependent interaction with steroid receptor coactivator-1. Pharmacogenet Genom 17(5):369-382
12. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR, Schuetz EG, Boguski MS (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11(7):555-72
13. Sandanaraj E, Lal S, Selvarajan V, Ooi LL, Wong ZW, Wong NS, Ang PCS, Lee EJD, Chowbay B (2008) PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14(1):7116-7126
14. Zhang B, Xie W, Krasowski MD (2008) PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9(11):1695-709
15. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PWN, O'Donoghue D, O'Sullivan M, O'Morain C, Mahmud N, Wikström AC, Kelleher D, McManus R (2006) The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130(2):341-348
16. He P, Court MH, Greenblatt DJ, von Moltke LL (2006) Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 46(11):1356-1369
17. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36(1):169-181
18. King C, Xiao M, Yu J, Minton M, Addleman N, Van Booven D, Kwok PY, McLeod H, Marsh S (2007) Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 63(6):547-554
19. Huwyler J, Wright MB, Gutmann H, Drewe J (2006) Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab 7(2):119-126
20. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K (2008) A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 36(8):1689-1697
21. Säll C, Houston JB, Galetin A (2012) A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos 40(7):1279-1289
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2001) Guidance for industry: statistical approaches to establishing bioequivalence: 9
23. He J, Qiu Z, Li N, Yu Y, Lu Y, Han D, Li T, Zhao D, Sun W, Fang F, Zheng J, Fan H, Chen X (2011) Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol 67(7):701-707
24. Wang ZJ, Yin OQ, Tomlinson B, Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genom 18(7):637-645
25. Scott LJ (2012) Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 72(2):249-272
26. Lukacova V, Woltosz WS, Bolger MB (2009) Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J 11(2):323-334